Post-transplant Lymphoproliferative Disorder
📧 Sign up to get email alerts when something new happens for Post-transplant Lymphoproliferative Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants [Phase 1]
Phase 1 trial of the BZLF1 peptide vaccine OSU-2131 with QS-21 to prevent Epstein-Barr virus–related cancers in patients awaiting solid orga…
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation [Phase 3]
A Phase 3 trial evaluating reduced immunosuppressive therapy with or without donor white blood cells in patients with post-transplant lympho…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
EVITA is a completed study monitoring Epstein-Barr virus infection in renal transplant recipients; the snippet does not include trial result…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas [Phase 2]
An open-label Phase 2 trial evaluating nanatinostat plus valganciclovir in EBV-positive relapsed/refractory lymphomas has been terminated, w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: A Study of the Safety and Efficacy of EBV Specific T-cell Lines [Phase 1, Phase 2]
A completed Phase 1/2 study evaluated the safety and efficacy of Epstein-Barr virus–specific T-cell lines in patients with Epstein-Barr viru…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder [Phase 2]
Phase 2 trial evaluating rituximab and acalabrutinib in newly diagnosed post-transplant lymphoproliferative disorder was terminated with res…
-
CLINICAL_TRIALS trial_result · 2022-08-02Clinical Trial Update: Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial [Phase 1, Phase 2]
Pilot trial investigating ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients; Phase 1/2 study with unk…
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder [Phase 2]
Phase 2 trial evaluating the combination of rituximab and LMP-specific T cells for EBV-positive, CD20-positive post-transplant lymphoprolife…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating high-dose Y-90 ibritumomab tiuxetan added to reduced-intensity allogeneic stem cell transplant for relapsed or refr…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas [Phase 2]
Phase 2 trial update of cellular immunotherapy targeting EBV in viral-induced cancers including various lymphomas; the study is terminated w…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders [Phase 2]
A Phase 2 trial evaluating the combination of bortezomib and rituximab for post-transplant lymphoproliferative disorders was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: aCGH Impacts Survival in Plasma Cell PTLD
A clinical trial update reports that array-based comparative genomic hybridization (aCGH) testing may influence survival outcomes in patient…
-
CLINICAL_TRIALS trial_result · 2015-04-13Clinical Trial Update: EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
This completed clinical trial evaluated Epstein-Barr virus infections as a risk factor for post-transplant lymphoproliferative disorder in p…
-
CLINICAL_TRIALS trial_result · 2013-03-19Clinical Trial Update: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating the combination of Beta-Glucan and Rituximab in young patients with relapsed or progressive leukemia or lymphoma, i…
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Yttrium-90 ibritumomab tiuxetan in combination with rituximab for post-transplant lymphoproliferative disorder …
-
CLINICAL_TRIALS trial_result · 2012-03-16Clinical Trial Update: Relationship Between EBV and PTLD
A pediatric heart transplant trial studying the relationship between Epstein-Barr virus and post-transplant lymphoproliferative disorder has…
-
CLINICAL_TRIALS trial_result · 2011-10-25Clinical Trial Update: Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) [Phase 2]
Phase 2 trial update on sequential treatment for CD20-positive post-transplant lymphoproliferative disorder, with the study status listed as…
-
CLINICAL_TRIALS trial_result · 2010-01-13Clinical Trial Update: Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant [Phase 1]
Phase 1 clinical trial evaluating cytotoxic T lymphocyte therapy for post-transplant lymphoproliferative disorder after liver transplantatio…